Table 1.
Demographic characteristics and therapeutic results.
| ADALIMUMAB COHORT (N=29) | USTEKINUMAB COHORT (N=21) | OVERALL (N=50) | |
|---|---|---|---|
| Gender (M/F) | 16/13 | 12/8 | 28/22 |
| Age (years; mean±SD) | 42 ± 9,7 | 44,5 ± 11,2 | 43 ± 12,4 |
| Family history (N,(%)) | 8, (27,6) | 11, (52,4) | 19, (38) |
| Disease duration (years; mean±SD) | 19,8 ± 9,2 | 17,2 ± 8,3 | 18,7 ± 8,6 |
| BMI (kg/m2; mean±SD) | 28,1 ± 1,5 | 27 ± 3,3 | 27,3 ± 2,1 |
| Previously failed: | |||
| TNFi | 4 | 10 | 14 |
| . Adalimumab | 0 | 8 | 8 |
| . Etanercept | 3 | 1 | 4 |
| . Infliximab | 1 | 1 | 2 |
| IL-12/23i | |||
| . Ustekinumab | 2 | 0 | 2 |
| Naïve | 23 | 11 | 34 |
| . NB-UVB | 10 | 9 | 19 |
| . PUVA | 1 | 2 | 3 |
| . Cyclosporine | 10 | 11 | 21 |
| . Methotrexate | 7 | 14 | 21 |
| . Acitretin | 4 | 1 | 4 |
| Reasons to discontinue Secukinumab | |||
| . Lack of efficacy at 16 weeks | 12 | 13 | 15 |
| . Loss of efficacy after 16 weeks | 13 | 7 | 20 |
| . Recurrent mucosal fungal infections | 2 | 3 | 5 |
| . Headache and hypertension | 3 | 2 | 5 |
| . Erysipelas | 2 | 0 | 2 |
| . Dizziness and nausea | 1 | 1 | 2 |
| . Hypertrigliceridemia | 0 | 1 | 1 |
| Secukinumab duration (months; mean±SD) | 45,8 ± 13,6 | 55,4 ± 3,7 | 49,6 ± 8,9 |
| Comorbidities | |||
| . Hypertension (N) | 2 | 2 | 4 |
| . Psoriatic arthritis (N) | 2 | 1 | 3 |
| . Diabetes mellitus (N) | 1 | 1 | 2 |
| . Emphysema (N) | 0 | 1 | 1 |
| Baseline | |||
| PASI (mean±SD) | 14,4 ± 4 | 16,8 ± 3,3 | 16,3 ± 3,7 |
| DLQI (mean±SD) | 18 ± 2,5 | 18,4 ± 1,2 | 18,4 ± 2,5 |
| Biologic naïve | |||
| PASI (mean±SD) | 15,5 ± 3,3 | 18,5 ± 3,6 | 16,7 ± 3,3 |
| DLQI (mean±SD) | 16 ± 2,7 | 14,3 ± 2 | 15,2 ± 2 |
| Previous TNF inhibitor | |||
| PASI (mean±SD) | 11 ±4,0 | 16 ± 2,4 | 14,1 ± 2,7 |
| DLQI (mean±SD) | 22 ±3 | 22 ± 3,2 | 22 ± 3 |
| Previous ustekinumab | |||
| PASI (mean±SD) | 15,5 ± 2,12 | - | 15,5 ± 2,12 |
| DLQI (mean±SD) | 21,5 ± 2,1 | - | 21,5 ± 2,1 |
| Week 52 | |||
| PASI (mean±SD) | 3,0 ± 0,6 | 3,2 ± 0,3 | 3,1 ± 0,4 |
| DLQI (mean±SD) | 7 ±0,7 | 4,1 ± 3,7 | 5,5 ± 2,8 |
| Biologic naïve | * | * | |
| PASI (mean±SD) | 2,8 ± 0,9 | 2,6 ± 0,3 | 2,7 ± 0,5 |
| DLQI (mean±SD) | 6 ± 2,3 | 4 ± 2 | 5 ± 2,2 |
| Previous TNF inhibitor | * | ||
| PASI (mean±SD) | - | 3,8 ± 0,2 | 3,8 ± 0,2 |
| DLQI (mean±SD) | - | 10 ± 2,1 | 10 ± 2,1 |
| Previous ustekinumab | |||
| PASI (mean±SD) | 3,1 ± 0,4 | - | 3,1 ± 0,4 |
| DLQI (mean±SD) | 8 ± 1,2 | - | 8 ± 1,2 |
F: Female, i:inhibitor, M: Male, N: number, SD: Standard Deviation, IL: Interleukin, BMI: Body Mass Index, TNF: Tumor Necrosis Factor, PASI: Psoriasis Area Severity Index, DLQI: Dermatologic Quality of Life , PUVA: psorialen and ultraviolet-A, NB-UVB: narrowband ultraviolet-B.